AKLIEF
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AKLIEF (AKLIEF).
AKLIEF (trifarotene) is a selective retinoic acid receptor (RAR) gamma agonist. It modulates gene expression by binding to RAR-gamma, leading to normalization of follicular keratinization, reduced comedogenesis, and anti-inflammatory effects.
| Metabolism | Trifarotene is metabolized primarily via CYP2D6 and to a lesser extent via CYP3A4. It undergoes extensive first-pass metabolism with low systemic exposure after topical application. |
| Excretion | Fecal: ~70% as unchanged drug; Renal: <1% as metabolites. |
| Half-life | Terminal elimination half-life: ~29 hours after topical application; supports once-daily dosing. |
| Protein binding | >99% bound to plasma proteins (primarily albumin and lipoproteins). |
| Volume of Distribution | Not determined for topical route; systemic absorption minimal with Vd not clinically relevant. |
| Bioavailability | Topical: ~1% systemic absorption; oral: not applicable. |
| Onset of Action | Clinical improvement noted within 2–4 weeks of once-daily topical application. |
| Duration of Action | Duration of action corresponds to dosing interval of 24 hours with sustained therapeutic effect; continued use required for maintenance. |
Apply a thin layer to affected areas once daily in the evening, avoiding eyes, lips, and mucous membranes.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required in renal impairment. Not studied in severe renal impairment. |
| Liver impairment | No dose adjustment required in mild to moderate hepatic impairment (Child-Pugh A, B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Approved for acne vulgaris in patients aged 12 years and older: apply a thin layer to affected areas once daily in the evening. |
| Geriatric use | No specific dose adjustment required; clinical studies did not include sufficient geriatric patients to determine differential response. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AKLIEF (AKLIEF).
| Breastfeeding | No data on excretion in human milk; M/P ratio unknown. Caution advised due to potential for serious adverse reactions in nursing infants. |
| Teratogenic Risk | Pregnancy Category C. First trimester: No adequate studies in humans; animal studies show embryofetal toxicity at high doses. Risk cannot be ruled out. Second and third trimesters: Limited data; avoid unless benefit outweighs risk. |
| Fetal Monitoring |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to trifarotene or any component of the formulation"]
| Precautions | ["Local skin reactions (erythema, scaling, dryness, stinging/burning) may occur; reduce frequency or discontinue if severe.","Avoid excessive exposure to sunlight or UV light; use sunscreens and protective clothing.","Avoid contact with eyes, mouth, angles of the nose, and mucous membranes.","Pregnancy: Limited data; no known risk of major malformations based on animal studies, but use only if clearly needed."] |
| Food/Dietary | No significant food interactions reported. Avoid excessive alcohol consumption as it may exacerbate skin dryness and irritation. No specific dietary restrictions. |
Loading safety data…
| Monitor maternal liver function tests, renal function, and complete blood count. Fetal ultrasound for growth and anatomy if exposure occurs during pregnancy. |
| Fertility Effects | Animal studies indicate no impairment of fertility at therapeutic doses; human data lacking. Reversible effects on spermatogenesis reported in animal models at high doses. |
| Clinical Pearls | AKLIEF (trifarotene) is a fourth-generation retinoid selective for RAR-γ receptors, minimizing irritation compared to tretinoin. Use pea-sized amount for entire face; avoid excessive application. Initiate every other night to improve tolerability. Concomitant use of benzoyl peroxide or salicylic acid may increase dryness; advise non-comedogenic moisturizers. Contraindicated in pregnancy (Category X); rule out pregnancy before starting. |
| Patient Advice | Apply a thin layer once daily at night to clean, dry skin. · Avoid sun exposure and use broad-spectrum SPF 30+ sunscreen daily. · May cause initial redness, peeling, and dryness; use moisturizer. · Do not use if pregnant or planning pregnancy; use effective contraception. · Do not apply to cuts, abrasions, or eczematous skin. · Avoid waxing or laser hair removal during treatment. · Therapeutic effect may take 8-12 weeks. · Keep out of reach of children and away from eyes, mouth, and mucous membranes. |